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ABSTRACT
Introduction. Psoriasis is a chronic inflammatory and immune-
mediated skin disease that affects over 7.2 million U.S. adults. Current 
treatment has improved clinical outcomes. Vitamin D is believed to 
affect the proliferation and regeneration of keratinocytes; therefore, 
its deficiency is a possible risk factor; however, there is still no definite 
evidence. The objective of this study was to synthesize existing data 
on the relationship between hypovitaminosis D and psoriasis.
Methods.xA meta-analysis of relevant studies was conducted by 
doing a comprehensive search in the MEDLINE, EMBASE, and the 
Cochrane Central Register through July 2018 to identify relevant 
cohort studies and to assess serum 25-hydroxyvitamin D (25(OH)
D) levels in adults with psoriasis. The primary outcome was the mean 
difference in serum 25(OH)D level between psoriatic patients and 
controls.
Results. The initial search identified 107 articles. Only ten studies 
met the criteria for full-paper review. Meta-analysis was conducted 
from ten prospective cohort studies involving 6,217 controls and 693 
cases. The pooled mean difference in serum 25(OH)D level between 
psoriatic patients and controls was -6.13 ng/ml (95% CI, -10.93 to 
-1.32, p-value = 0.01). The between-study heterogeneity (I2) was 
98%, p < 0.00001.
Conclusion. Our meta-analysis was the first study to establish the 
relation between vitamin D and psoriasis. The result found a signifi-
cant relationship between low 25(OH) D levels and psoriasis, but did 
not establish a causal relationship. Further studies will be required 
to establish whether vitamin D supplementation benefits patients 
with psoriasis. 
Kans J Med 2019;12(4):103-108.
INTRODUCTION
Hypovitaminosis D is common in the United States and Euro-
pean countries, especially in the winter.1,2 Vitamin D deficiency 
is considered one of the risk factors for osteoporosis. In addition, 
hypovitaminosis D has been associated with a variety of autoimmune 
diseases such as rheumatoid arthritis, Crohn’s disease, system-
ic lupus erythematosus, and multiple sclerosis.3-5 There are also 
several reports on the association between hypovitaminosis D and 
autoimmune skin conditions, such as pemphigus vulgaris, bullous 
pemphigus, alopecia areata, and vitiligo.6-8 Vitamin D may have an 
essential role in modulating dendritic cell function, and regulating 
keratinocytes and T-cell proliferation that can lead to skin pathol-
ogy.9 This may be one of the explanations for the association between 
hypovitaminosis D and autoimmune diseases. 
Psoriasis is considered a chronic inflammatory and immune-medi-
ated skin disease that affects 3.2% of the U.S. population, or over 7.2 
million adults over the age of 20.10 There is increasing evidence that 
psoriasis is a systemic disorder, like other inflammatory diseases, 
such as rheumatoid arthritis and systemic lupus erythematosus, that 
can affect every ethnicity.11 Clinical improvement of psoriasis fol-
lowing sun exposure, which may be due to a decrease in cutaneous 
lymphocyte-associated antigen (CLA)+ T cells, has been reported.12 
This clinical improvement also might be due to increased vitamin 
D production in the skin following sun exposure.4,13,14 Moreover, 
some studies have identified an association between polymorphisms 
of vitamin D receptor (VDR) and the severity of psoriasis disease, 
believing it affects the alteration of the cutaneous barrier.15-16 The 
hypotheses about Vitamin D and its properties as an inflamma-
tion modulator16 may link to the pathogenesis and disease activity 
of psoriasis. From multiple literature reviews, we acknowledge an 
important relationship between vitamin D and psoriasis; however, 
there are no clear-cut data or evidence that hypovitaminosis D defi-
nitely is related to psoriasis. We conducted the first systematic review 
and meta-analysis to determine whether there was an association 
between hypovitaminosis D and psoriasis.
METHODS
A systematic review and meta-analysis were conducted and 
reported according to the Preferred Reporting Items for Systemic 
Reviews and Meta-Analyses (PRISMA) guidelines.17
Eligibility Criteria. In this meta-analysis, studies were included 
that assessed serum vitamin D concentration (25-hydroxyvitamin D; 
25(OH)D) or vitamin D deficiency in patients with psoriasis. Studies 
that met the following criteria were included: 
(1) Human studies that included adult participants ≥ 18 years of 
age who had been diagnosed with psoriasis and normal controls 
and had serum 25(OH)D level measured.
(2) Prospective cohort, retrospective cohort, case-control, and 
cross-sectional studies in English.
(3) Reported outcomes including serum 25(OH)D levels in both 
cases and controls.
Literature Search and Selection. The search was conducted 
independently by two reviewers (SP and SP). Published studies 
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License. (CC-BY-NC-ND 4.0: https://creativecommons.
org/licenses/by-nc-nd/4.0/)
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ter of Controlled Trials (CENTRAL) up to July 2018 were used as 
a database. One hundred seven relevant studies were selected. Dif-
ferences in literature inclusion/exclusion were decided by consensus. 
Search keywords included: psoriasis, vitamin D, 25-hydroxyvitamin D, 
1,25-dihydroxyvitamin D, 25(OH)D, ergocalciferol, and cholecalcifer-
ol. No restrictions on languages were included in the search strategies. 
References of selected studies were reviewed carefully as well. After 
the search, two authors (SP, SP) independently reviewed abstracts and 
all relevant references. The full-text evaluation was undertaken when 
abstracts did not provide adequate information regarding eligibility 
criteria. Any disagreements on selected studies were resolved by a dis-
cussion between the two reviewers for final selection.
Risk of Bias and Quality Assessment. Two authors (SP, SP) 
independently assessed the quality of each study using the Newcastle-
Ottawa Scale for assessing the quality of nonrandomized studies in 
meta-analyses.18 A study that received seven or more stars was consid-
ered a high-quality study, four to six stars a moderate quality study, and 
zero to three stars a poor-quality study. The minimum score of included 
studies was six and the maximum was nine. Seven studies were consid-
ered high-quality and three studies were considered moderate-quality. 
Quality assessment scores using the Newcastle-Ottawa Scale tool for 
observational studies are reported in Tables 1 and 2. 
Statistical Methods. Meta-analysis was performed using Review 
Manager 5.3 software from the Cochrane Collaboration (London, 
UK). The studies were reported as the standardized mean differences 
(SMD) with 95% confidence intervals (CI) comparing between two 
groups. Parameter estimates from studies were plotted using forest 
plots to evaluate the difference of vitamin D level between psoriatic 
patients and normal controls. Publication bias was evaluated using 
Egger’s test. Heterogeneity of effect size was interpreted through I2 
and Q Statistic. Random effects models were used.  Subgroup analysis 
was not performed due to the insufficient number of eligible studies.
RESULTS
Systematic Review of the Literature. Ten studies were identified 
for inclusion in this review.19-28 The initial search yielded 107 articles 
(Figure 1); 85 were discarded because the abstracts did not meet the 
criteria. The full text of 22 articles was examined in more detail. Twelve 
studies did not meet the inclusion criteria as described. Ten studies met 
the inclusion criteria and were included in the review. The references of 
the ten studies also were reviewed. No relevant studies were obtained 
from these references. Data were extracted from ten studies, and a total 
of 6,217 controls and 693 cases from these studies were included in the 
meta-analysis. The characteristics of extracted studies included in this 
review are reported in Table 3.
Outcome. The extracted data regarding serum 25(OH)D level in 
psoriasis and control groups are presented in Table 4. 
Meta-analysis. Ten studies were included in the meta-
analysis of serum 25(OH) D (Figure 2). The pooled mean 
difference in serum 25(OH) D level was -6.13 ng/ml (95% con-
fidence interval, -10.93 to -1.32, p = 0.01), lower in patients with 
psoriasis than in the control participants; the between-study 
heterogeneity (I2) was 98%, p = value < 0.00001.
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Figure 1. Flow diagram of search results and screening process.
Publication Bias. To investigate potential publication bias, we 
used Egger’s test instead of funnel plot due to more accurate mean 
difference data. The Egger’s test did not show a significant bias with 
p = 0.051 for the pooled mean difference in serum 25(OH) D (Figure 
3).
DISCUSSION
Low vitamin D levels have been associated with several auto-
immune diseases, including rheumatoid arthritis, Crohn’s disease, 
systemic lupus erythematosus, and multiple sclerosis.3-5 In addition, 
there have been reports on the association between hypovitamino-
sis D and autoimmune skin conditions such as pemphigus vulgaris, 
bullous pemphigus, alopecia areata, and vitiligo.6-8 A potential link 
between vitamin D deficiency and psoriasis also has been reported.15 
The major finding of our systematic review and meta-analysis was 
that there is a significant relationship between low 25(OH) D levels 
and psoriasis. Our meta-analysis revealed that the serum vitamin D 
level was significantly lower in psoriatic patients compared to control 
patients. To the best of our knowledge, there is no previous system-
atic review and meta-analysis of the relationship between vitamin D 
levels and psoriasis.
Vitamin D is generally classified into two types, vitamin D2 (ergo-
calciferol) and D3 (cholecalciferol). Vitamin D2 (ergocalciferol) is 
not produced in the human body; whereas vitamin D3 (cholecalcifer-
ol) is synthesized in the skin from 7-dehydrocholesterol by ultraviolet 
light and is the primary source of vitamin D3 in humans. The other 
source of vitamin D3 is exogenous intake from food and supple-
ments.29 Vitamin D is essential for the maintenance of health. Vitamin 
D is necessary for the absorption of calcium in the small intestine, 
and it increases bone resorption and the release of calcium into the 
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Table 1. Newcastle-Ottawa Scales adapted for cross-sectional studies. 
Study
Selection Comparability Exposure
Total
Representativeness of the 
sample
Justified 
sample 
size
Ascertainment of 
exposure
Comparable 
non-
respondents 
rate between 
two groups
Comparability of 
different samples on 
the basis of the design 
or analysis
Assessment of outcome
Appropriate 
statistical 
test
Truly 
representative
Somewhat 
representative
Validated 
measurement 
tool (two 
stars)
Non-
validated 
tool
Study 
controls 
for the 
most 
important 
factor
Study 
controls 
for any 
additional 
factor
Independent 
blind 
assessment 
(two stars)
Record 
linkage 
(two 
stars)
Self-
report
Wilson 
et al.19 * * ** * * * * 8
Table 2. Newcastle-Ottawa Scales adapted for case-control studies. 
Study
Selection Comparability Exposure
TotalAdequate 
case 
definition
Representativeness of 
the cases
Selection of 
controls
Definition 
of controls
Study 
controls for 
the most 
important 
factor
Study 
controls 
for any 
additional 
factor
Ascertainment 
of exposure (max 
of 2 stars)
Same method of 
ascertainment for 
cases and controls
Non-
response 
rate
Solak et al.20 * * * * * * * 7
Maleki et al.21 * * * * * * * 7
Petho et al.22 * * * * * ** * * 9
Zuchi et al.23 * * * * * * 6
Chandrashekar 
et al.24 * * * * * * * 7
El-Moaty 
Zaher et al.25 * * * * * * 6
Al-Mutairi et 
al.26 * * * * * * * 7
Gisondi et al.27 * * * * * * 6
Orgaz-Molina 
et al.28 * * * * * * * * 8
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blood by stimulating osteoclast maturation. Apart from calcium 
homeostasis, there has been evidence that vitamin D may have an 
essential role in cell maturation and immunity.30 Also, vitamin D 
receptor (VDR) expression has been found in various human tissues 
including immune cells.31
The role of vitamin D in the skin has been studied widely within 
the past decades.15,32 The active form of vitamin D regulates kerati-
nocyte proliferation, differentiation, and apoptosis. Several reports 
in vitro and vivo studies found a dose-dependent relation between 
these effects.33,34 The pathogenesis of psoriasis involves an abnormal 
function of an innate and adaptive segment of the immune system 
which T- lymphocyte cell is the central primary controller for these 
immune processes.12 Subtypes of T-cell, including T-helper (Th)1, 
Th17 and Th22, interact with numerous cells through cytokines, 
such as tumor necrosis factor-α (TNF-α), interleukin (IL) -6 and 
IL-17.35 The defect of the T-cell function can cause abnormal skin 
regeneration.36-37 Vitamin D also acts as a pluripotent immunomodu-
lator that can inhibit proliferation of T-cell lymphocyte and induce 
regeneration of CD25+/CD4+ regulatory T-cell that preserves/con-
trols immunological homeostasis and prevents autoimmune response 
against self-antigens.38-39 In addition to T-cell regulation, vitamin D 
has a vital role in inflammatory function. Its metabolite is respon-
sible for down-regulating the production and expression of TNF-α, 
IL-1β, IL-6, IL-8, and inflammatory profile of human monocytes/
macrophages.35,40 Finally, vitamin D also helps to protect skin from 
opportunistic infections by inducing autophagy in macrophages and 
normalize innate response of skin barrier integrity and permeability.16
The treatment of psoriasis by exposure to UV rays and sunlight 
has been known for decades, and the mechanism may be a vitamin 
D effect related to an increase in endogenous vitamin D synthesis in 
the skin.41 Also in the standard treatment of psoriasis, topical vitamin 
D has been used as a first-line, single or combination medication 
with topical corticosteroid on localized plaque lesion.42 However, the 
effect of vitamin D supplements in treating psoriasis is unclear, but 
positive outcomes after the treatment for psoriasis-related comor-
bidities have been reported including hypertension and metabolic 
syndrome.43-45 Another association between low vitamin D level and 
psoriasis might be explained by the hypothesis that vitamin D modu-
lates immune responses in certain conditions.46 Low vitamin D levels 
possibly increase the risk of various autoimmune diseases, including 
psoriasis. Also, a high daily dose of vitamin D supplement improved 
Psoriasis Area and Severity Index (PASI) scores significantly in 
patients with psoriasis.47 Our study with a large number of patients 
found a significant association between low vitamin D levels and pso-
riasis that support previous studies.
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Table 3. Characteristics of the included studies. 
Study Study design Location
Sample Size (n)
Age (years) Duration of disease (years) Type of psoriasis Controls
25(OH)D cutoff 
(ng/mL)Psoriasis Controls
Solak et al.20 Case-control Turkey 43 41 36.72 ± 8.00
0 - 5 years: 8 
(18.6%)
6 - 10 years: 16
(37.21%)
> 10 years: 19
(44.19%)
Psoriasis without 
arthritis Matched with age NA
Maleki et al.21 Case-control Iran 50 43 42.80 ± 13.68 10.37 ± 9.87 Chronic plaque psoriasis
Age- and sex-matched 
controls from northeast-
ern Iran
Deficiency 
(< 20 ng/mL)
Petho et al.22 Case-control Hungary 53 53 54.7 (31 - 84) 10.8 Psoriatic arthritis
Age- and gender-
matched healthy 
volunteers
Hypovitaminosis D 
(< 30 ng/mL)
Zuchi et al.23 Case-control Brazil 20 20 46.40 ± 14.90 3.5 ± 9
25% palmoplantar 
psoriasis; 75% 
psoriasis vulgaris
Healthy individuals
Deficiency (< 20 
ng/mL); insuf-
ficiency (20 to < 30 
ng/mL); sufficiency 
(≥ 30 ng/mL)
Chandrashekar 
et al.24 Case-control India 43 43 44.6 ± 12.0 4.1375 ± 4
Fitzpatrick skin 
type V
Age- and gender-
matched healthy 
volunteer
NA
El-Moaty 
Zaher et al.25 Case-control Egypt 48 40 43.88 ± 15.157 NA
Histopathologically 
proven psoriasis
Age-, sex-, skin proto-
type- and socioeconom-
ic-match individuals
NA
Al-Mutairi et 
al.26 Case-control Kuwait 100 100 42
12.2 (0.3 - 
31.3)
Plaque psoriasis 
with Fitzpatrick 
skin types III to V
Age- and sex-matched 
healthy controls
Deficiency (< 10 
ng/mL)
Gisondi et al.27 Case-control Italy 145 141 51.9 ± 13.3 19.8 ± 13.1 Chronic plaque psoriasis
The partners or rela-
tives of patients if not 
affected by psoriasis
Deficiency (< 20 
ng/mL)
Orgaz-Molina 
et al.28 Case-control Spain 43 43 44.33 ± 8.71 19.91
Fitzpatrick skin 
phototype II, III, 
or IV
Randomly selected 
age- and sex-matched 
controls with non-
photosensitive 
dermatologic diseases 
other than psoriasis
Deficiency (< 10 
and < 20 ng/mL); 
insufficiency (< 30 
ng/mL)
Wilson et al.19 Cross-sectional USA 148 5,693 20 - 59 NA NA
Participants without 
psoriasis
Deficiency (< 20 
and < 30 ng/mL)
Table 4. The outcomes of the included studies. 
Study
Vitamin D Deficiency 25(OH)D (ng/mL)
P value
Psoriasis Control Psoriasis Control
Solak et al.20 Deficiency NA; Insufficiency NA Deficiency NA; Insufficiency NA 21.2 ± 8.7 25.2 ± 14.1 0.12
Maleki et al.21 Deficiency 84%; Insufficiency NA Deficiency 93%; Insufficiency NA 14.92 ± 6.31 12.52 ± 4.54 0.21
Petho et al.22 Hypovitaminosis D 81% Hypovitaminosis D 57% 21.4 ± 9.23 28.3 ± 14.43 0.001
Zuchi et al.23 Deficiency 25%; Insufficiency 65% Deficiency 20%; Insufficiency 60% 23.55 ± 7.60 22.35 ± 3.10 0.7356
Chandrashekar et al.24 Deficiency NA; Insufficiency NA Deficiency NA; Insufficiency NA 13.3 ± 6.9 22.4 ± 18.4 0.004
El-Moaty Zaher et al.25 Deficiency NA; Insufficiency NA Deficiency NA; Insufficiency NA 21.05 ± 3.66 37.02 ± 5.06 < 0.05
Al-Mutairi et al.26 Deficiency 12%; Insufficiency NA Deficiency 9%; Insufficiency NA 12.8 ± 5.6 21.6 ± 8 < 0.005
Gisondi et al.27 Deficiency 57.8% Deficiency 29.7% 20.7 ± 11.3 37.1 ± 27.6 0.001
Orgaz-Molina et al.28 Deficiency 25.6%; Insufficiency 79.1% Deficiency 9.3%; Insufficiency 58.1% 24.41 ± 7.80 29.53 ± 9.38 0.007
Wilson et al.19 < 20 33%; < 30 72.5% < 20 34.9%; < 30 76.4% 24.2 ± 1.5 23.6 ± 0.9 0.37
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Figure 2. Pooled mean differences in serum 25-hydroxyvitamin D level between patients with psoriasis and control participants. 
Figure 3. Egger’s test results revealing no publication bias.
Regarding a positive relation between hypovitaminosis D and 
psoriasis, our study had several limitations. First, though all data 
from the international literature were included, the largest study 
was conducted by Wilson et al.19 retrieving information from the 
National Health and Nutrition Examination Survey (NHANES). 
Therefore, all information was extracted from people who reside in 
the U.S. at only one point in time as is the nature of a cross-sectional 
study. Also, the data were collected through surveys on the severity 
of psoriasis without knowing the duration of disease, psoriasis type, 
and the majority of the patients reported having mild disease. Con-
sequently, the study may have response bias and voluntary response 
bias. Even though the conclusion of this study favors the control 
group as shown in the forest plot (Figure 2) and serum vitamin D 
level (Table 4), there was no statistically significant difference which 
can be explained by a very small number of psoriasis patients (148 
individuals) compared with the control group (5,693 individuals). 
Since this study19 was discrepant and unclear regarding the associa-
tion between psoriasis and vitamin D deficiency, our meta-analysis 
attempted to include all the available studies to analyze the result. 
Furthermore, the limitation of multiple unknown confounding vari-
ables inherent in a meta-analysis on studies involving different de-
signs, differing follow-up periods, and differing patient demographic 
populations with diverse epidemiologic and clinical characteristics 
also should be determined.
CONCLUSION
In summary, this systematic review and meta-analysis indicated 
that there is a significant relationship between low 25(OH) D levels 
and psoriasis. However, it is unclear whether low vitamin D level is a 
pathophysiologic cause of psoriasis. The etiology of psoriasis remains 
unclear and is likely multifactorial.15 Low vitamin D levels might be 
one of the causes of psoriasis. Based on our findings, it would be 
important to measure serum 25(OH) D levels in psoriatic patients 
not only to provide supplementation but also to prevent other com-
plications associated with vitamin D deficiency. 
Further research should investigate whether there is a causal rela-
tionship between vitamin D deficiency and psoriasis and whether 
therapeutic vitamin D supplementation in patients with psoriasis 
reduces the disease burden.
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